About the Journal

Annals of Cancer Epidemiology

Aims and Scope

The Annals of Cancer Epidemiology (Ann Cancer Epidemiol; ACE; ISSN: 2616-4213) is an international, peer-reviewed, open-access journal with the goal to help human apply epidemiological studies to fight against cancers by providing an open-access platform and user-friendly facilities to worldwide cancer researchers, clinicians, scientists and policy makers, and shape an effective communication and collaboration amongst them.

The scope of Annals of Cancer Epidemiology includes but not limited to the following aspects: cancer statistics, descriptive epidemiology, studies of affecting factors for diseases, prevention, evaluation of interventions, screening, early detection, precise diagnosis, methodological issues and theory, etc.

All submissions and review processes of ACE are conducted electronically to expedite the reviews and publication process. ACE will spare no effort to minimize the duration of review and publication processes whilst maintaining the highest standards of each, and will maintain innovative efforts to meet readers’ need.

The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold ACE articles to the high-quality standards. ACE welcomes submissions of Original Research (full length and brief reports), Review Articles and Editorials to published research. For descriptions and length requirements of the article types, please refer to the journal’s Author Instructions.

Information for Authors

ACE is a member of the International Committee of Medical Journal Editors (ICMJE) and follows the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal and the Committee on Publication Ethics (COPE)'s guidelines.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Submission Turnaround Time

  • Submission to First Editorial Decision: 1-3 weeks.
  • External peer review: 1-3 months.
  • Acceptance to Publication: 1-4 weeks. Original Articles are listed as priority.

Open Access Statement

Annals of Cancer Epidemiology is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.
The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Copyright

For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to ACE, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For any inquiry/special circumstance on the copyright, commercial usage or adaptation of ACE articles, please contact: permissions@amegroups.com

For reprint order, please contact: sales@amegroups.com

Editorial Office

Email: ace@amegroups.com
Phone: +86 20 66355775

Publisher Information

ACE is published by AME Publishing Company.
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.


Updated on April 01, 2020